262 related articles for article (PubMed ID: 29088580)
1. Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease.
Eder L; Joshi AA; Dey AK; Cook R; Siegel EL; Gladman DD; Mehta NN
Arthritis Rheumatol; 2018 Mar; 70(3):408-416. PubMed ID: 29088580
[TBL] [Abstract][Full Text] [Related]
2. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.
Dey AK; Joshi AA; Chaturvedi A; Lerman JB; Aberra TM; Rodante JA; Teague HL; Harrington CL; Rivers JP; Chung JH; Kabbany MT; Natarajan B; Silverman JI; Ng Q; Sanda GE; Sorokin AV; Baumer Y; Gerson E; Prussick RB; Ehrlich A; Green LJ; Lockshin BN; Ahlman MA; Playford MP; Gelfand JM; Mehta NN
JAMA Cardiol; 2017 Sep; 2(9):1013-1018. PubMed ID: 28564678
[TBL] [Abstract][Full Text] [Related]
3. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Cook R; Gladman DD
Ann Rheum Dis; 2015 Oct; 74(10):1830-5. PubMed ID: 24827532
[TBL] [Abstract][Full Text] [Related]
4. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
5. Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT.
Hetterich H; Rominger A; Walter L; Habs M; Volpers S; Hacker M; Reiser MF; Bartenstein P; Saam T
Int J Cardiovasc Imaging; 2016 Jan; 32(1):49-59. PubMed ID: 25898891
[TBL] [Abstract][Full Text] [Related]
6. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.
Ramonda R; Puato M; Punzi L; Rattazzi M; Zanon M; Balbi G; Ortolan A; Frallonardo P; Faggin E; Plebani M; Zaninotto M; Lorenzin M; Pauletto P; Doria A
Joint Bone Spine; 2014 Oct; 81(5):421-5. PubMed ID: 24703399
[TBL] [Abstract][Full Text] [Related]
7. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
8. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
9. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
Bissonnette R; Tardif JC; Harel F; Pressacco J; Bolduc C; Guertin MC
Circ Cardiovasc Imaging; 2013 Jan; 6(1):83-90. PubMed ID: 23204039
[TBL] [Abstract][Full Text] [Related]
10. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
11. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
12. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
13. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
17. Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis.
Cheng IT; Shang Q; Li EK; Wong PC; Kun EW; Law MY; Yip RM; Yim IC; Lai BT; Ying SK; Kwok KY; Li M; Li TK; Zhu TY; Lee JJ; Chang MM; Szeto CC; Yan BP; Lee AP; Tam LS
Arthritis Rheumatol; 2019 Feb; 71(2):271-280. PubMed ID: 30144299
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
Hellamand P; van de Sande MGH; Ørnbjerg LM; Klausch T; Eklund KK; Relas H; Santos MJ; Vieira-Sousa E; Loft AG; Glintborg B; Østergaard M; Lindström U; Wallman JK; Michelsen B; Fagerli KM; Castrejón I; Gudbjornsson B; Love TJ; Vencovský J; Nekvindová L; Rotar Ž; Tomšič M; Díaz-González F; Kenar G; Tuğsal HY; Iannone F; Ramonda R; Codreanu C; Mogosan C; Nissen MJ; Möller B; Hetland ML; van der Horst-Bruinsma IE
Arthritis Rheumatol; 2024 Apr; 76(4):587-598. PubMed ID: 37975166
[TBL] [Abstract][Full Text] [Related]
19. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease.
Eder L; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Nov; 73(11):1990-6. PubMed ID: 23887287
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
